Who Owns Unigene Laboratories, Inc. Remnant Assets?
Oak Point Partners, Inc. acquired the remnant assets of the Unigene Laboratories, Inc. Bankruptcy Estate in October 2016.
On July 2, 2013, Unigene filed a voluntary petition for relief under chapter 7 of the Bankruptcy Code in the United States Bankruptcy Court for the District of New Jersey, assigned Case No. 13-24696. On July 8, 2013, a Trustee was appointed to administer the remaining assets of the Bankruptcy Estate. Oak Point Partners, Inc. acquired the remnant assets of the Unigene Laboratories, Inc. Bankruptcy Estate in October 2016.
Related Entities: Unigene Biotechnologies, Unigene Therapeutics
Contact Information Regarding Payments to Unigene Laboratories, Inc.
Inquiries regarding where to send: Overpayments, Undeliverable Funds, Insurance Refunds, Refunds, Warrants, Unclaimed Funds, Rebates, Uncashed Checks, Restitution, Credit Balance, Escheat, Judgment Balance, Abandoned Property, Settlement Proceeds, or any other funds belonging to Unigene Laboratories, Inc..
Requests for reasonable referral or finder fees will be considered.
Contact Info: Unigene Laboratories, Inc.
About Unigene Laboratories, Inc.
Founded in 1980, Unigene was a leading biopharmaceutical company that designed and manufactured peptide-based therapeutics. The company’s primary focus was on the development of calcitonin and related peptides for the treatment of osteoporosis. Unigene employed over 50 people.
Unigene also operated as Unigene Biotechnologies and Unigene Therapeutics
The former headquarters of Unigene was located in Boonton, NJ, and also had corporate addresses in Boonton and Fairfield, NJ.